Sector Chart Aligos Therapeutics, Inc.

Stocks

ALGS

US01626L2043

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 16:00:00 2026-07-24 EDT			5-day change	1st Jan Change
4.080 ^USD	-13.01%		-28.92%	-56.22%

07-13	Aligos Therapeutics Completes Enrollment In Phase 2 B-SUPREME Study Of Pevifoscorvir Sodium For Chronic HBV Infection	CI
07-13	Aligos Therapeutics Completes Enrollment in Phase 2 Study of Potential Chronic Hepatitis B Treatment	MT

Total Return

"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes

Sector Other Biotechnology & Medical Research

	Capi.	Sales Growth	Profitability	Finances	EV / Sales	P/E
ALIGOS THERAPEUTICS, INC.	25.25M				-	-
LONZA GROUP AG	46.86B
REVOLUTION MEDICINES, INC.	40.23B	-	-	-	-	-
BEONE MEDICINES AG	36.23B
IQVIA HOLDINGS INC.	34.72B
CELLTRION, INC.	27.89B